Welcome to our dedicated page for Enovix Corporation SEC filings (Ticker: ENVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enovix Corporation filings document the regulatory disclosures of an advanced lithium-ion battery manufacturer commercializing silicon-anode battery architectures. Recent Form 8-K reports cover operating results, Regulation FD updates, customer qualification and commercial updates, executive changes, manufacturing-scale communications and board-authorized capital actions.
The filing record also includes capital-structure disclosures related to convertible senior notes, warrants to purchase common stock, share repurchase plans and common-stock matters. Proxy materials document board elections, executive compensation, equity awards and shareholder voting items, while current reports provide formal exhibits for press releases and material agreements.
MCCRANIE J DANIEL reported acquisition or exercise transactions in this Form 4 filing.
Enovix Corp director J. Daniel McCranie received an equity grant in the form of restricted stock units (RSUs). On June 11, 2026 he was awarded 29,104 RSUs of Enovix common stock at no cash cost as part of his compensation. Each RSU represents a contingent right to receive one share of common stock, with 25% vesting on each of September 11, 2026, December 11, 2026, March 11, 2027, and the earlier of June 11, 2027 or the 2027 annual stockholders meeting, subject to continued service. Following this grant, he held 69,982 shares in total, including 48,379 shares issuable upon settlement of RSUs.
Enovix Corp director Joseph Ian Malchow reported an equity grant of 29,104 shares of common stock at no cost, classified as a grant/award acquisition. Following this award, his directly held common stock position is 467,367 shares.
Footnotes explain these are shares issuable upon settlement of restricted stock units, each equal to one Enovix common share. The RSUs vest in four 25% installments on September 11, 2026, December 11, 2026, March 11, 2027 and June 11, 2027 (or the 2027 annual meeting reference date), subject to continued service. The filing also notes 1,300 shares held indirectly for a minor child.
Enovix Corp director Gregory Reichow reported an equity grant of 29,104 restricted stock units (RSUs) with no cash exercise price. Each RSU represents one share of common stock, and this award brings his reported holdings, including RSUs, to 87,385 shares.
The RSUs vest in four equal installments of 25% on September 11, 2026, December 11, 2026, March 11, 2027, and the earlier of June 11, 2027 or the company’s 2027 annual stockholder meeting, subject to continued service. Under an agreement with Eclipse Ventures, LLC, the RSUs are held for Eclipse’s benefit, and Reichow disclaims beneficial ownership beyond any pecuniary interest.
GUTMANN BERNARD reported acquisition or exercise transactions in this Form 4 filing.
Enovix Corp director Bernard Gutmann received a grant of 29,104 restricted stock units (RSUs) on common stock as compensation. The RSUs vest in four equal installments on September 11, 2026, December 11, 2026, March 11, 2027, and the earlier of June 11, 2027 or the 2027 annual stockholder meeting date, subject to continued service. After this award, Gutmann holds 99,063 shares in total, including 30,766 shares issuable upon settlement of existing RSUs.
Ebrahimi Pegah reported acquisition or exercise transactions in this Form 4 filing.
Enovix Corp director Pegah Ebrahimi reported receiving a grant of 29,104 restricted stock units (RSUs), each representing one share of Enovix common stock. The RSUs were granted at $0.00 per share as part of equity compensation, not an open-market purchase.
The RSUs will vest in four equal installments of 25% on September 11, 2026, December 11, 2026, March 11, 2027, and the earlier of June 11, 2027 or the company’s 2027 annual stockholders’ meeting, subject to her continuous service as a director. After this award, she holds 102,043 shares of Enovix common stock, including shares underlying these RSUs.
Enovix Corp director Betsy S. Atkins received an equity award of 29,104 restricted stock units (RSUs) on common stock on June 11, 2026. The grant carries no cash exercise price, and each RSU represents a contingent right to one Enovix common share.
According to the vesting schedule, 25% of the RSUs will vest on each of September 11, 2026, December 11, 2026, March 11, 2027, and the earlier of June 11, 2027 or the date of Enovix’s 2027 annual stockholders meeting, subject to Atkins’ continuous service as a director. Following this grant, she holds 151,144 Enovix shares, including shares issuable upon RSU settlement.
Rodgers Thurman J reported acquisition or exercise transactions in this Form 4 filing.
Enovix Corp director and 10% owner Thurman J. Rodgers received a grant of 29,104 restricted stock units (RSUs) of Enovix common stock. The award was granted on June 11, 2026 at a price of $0.00 per share as compensation, not an open‑market purchase.
Each RSU represents a contingent right to receive one Enovix common share. Vesting will occur in four equal 25% installments on September 11, 2026, December 11, 2026, March 11, 2027, and the earlier of June 11, 2027 or the date of Enovix’s 2027 annual stockholder meeting, subject to his continued service.
Following this grant, Rodgers directly holds 34,740 Enovix common shares, including the 29,104 shares underlying the RSUs. He also has indirect ownership through two trusts where he serves as trustee with voting and dispositive power, holding 1,120,114 and 20,875,314 Enovix common shares, respectively.
Enovix Corp Chief Accounting Officer Kristina Truong reported a routine tax-related share adjustment. On the vesting of restricted stock units, 253 shares of common stock were withheld to cover tax obligations at $6.28 per share. After this withholding, she holds 315,369 common shares, including 220,610 shares tied to unvested RSUs and earned performance RSUs scheduled for release between March 2027 and April 2028.
Enovix Corporation reported the results of its 2026 Annual Meeting of Stockholders. Holders of 153,161,477 common shares, representing 70.3% of voting power as of the April 13, 2026 record date, were present in person or by proxy, establishing a quorum.
Stockholders elected all eight director nominees to one-year terms, with each receiving more votes "for" than "withheld." They also approved, on an advisory basis, the compensation of the company’s named executive officers. In addition, stockholders ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending January 3, 2027.
Enovix Corp President and CEO Rajendra K. Talluri had 4,301 shares of common stock withheld on June 8, 2026 to cover tax obligations tied to vesting restricted stock units (RSUs). The shares were valued at $7.32 each for the withholding calculation.
After this tax-withholding disposition, Talluri holds 3,062,266 shares directly, a figure that includes 1,989,823 shares issuable upon vesting and settlement of RSUs. His position also reflects 47,775 vested performance RSUs scheduled for release in March 2027 and 259,611 additional performance RSUs, half to be released in April 2027 and the rest in April 2028.